Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 15/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 15/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | EIF4E | P06730 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071119 | 0.89 | MKNK1 (0.52) | MKNK1MKNK2CYP3A4ADORA2A | |
| SCHEMBL31555 | 0.88 | MKNK1 (0.62) | MKNK1MKNK2CYP3A4EIF4EADORA2A | |
| SCHEMBL15071118 | 0.87 | MKNK1 (0.53) | MKNK1MKNK2CYP3A4EIF4EADORA2A | |
| SCHEMBL15071123 | 0.86 | HPGD (0.56) | MKNK1MKNK2CYP3A4ADORA2A | |
| SCHEMBL20146791 | 0.86 | MKNK1 (0.84) | MKNK1MKNK2 | |
| SCHEMBL15071121 | 0.85 | HPGD (0.54) | MKNK1MKNK2CYP3A4EIF4EADORA2A | |
| SCHEMBL31503 | 0.84 | ADORA2A (0.53) | MKNK1MKNK2ADORA2AGRM5 | |
| SCHEMBL20412795 | 0.82 | MKNK1 (0.76) | MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL15071125 | 0.81 | PLA2G7 (0.54) | MKNK1MKNK2ADORA2A | |
| SCHEMBL15071132 | 0.79 | F2RL1 (0.64) | MKNK1MKNK2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | MKNK1 1943/4885MKNK2 1249/4885CYP3A4 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.